Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned an average recommendation of “Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $107.00.

MNPR has been the topic of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a research report on Thursday, January 29th. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a research report on Wednesday, January 21st. Raymond James Financial lowered shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and dropped their price objective for the company from $142.00 to $123.00 in a report on Friday, November 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd.

Monopar Therapeutics Trading Up 1.5%

Shares of Monopar Therapeutics stock opened at $57.75 on Tuesday. Monopar Therapeutics has a twelve month low of $26.06 and a twelve month high of $105.00. The firm has a market capitalization of $385.77 million, a PE ratio of -16.79 and a beta of 1.52. The firm’s 50-day moving average price is $69.25 and its 200 day moving average price is $66.17.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, sell-side analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Activity at Monopar Therapeutics

In other Monopar Therapeutics news, CFO Quan Anh Vu acquired 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The shares were purchased at an average cost of $69.95 per share, for a total transaction of $104,925.00. Following the completion of the acquisition, the chief financial officer owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Monopar Therapeutics

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. purchased a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets raised its position in Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics during the second quarter worth $34,000. AlphaQuest LLC lifted its stake in Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after purchasing an additional 569 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.